Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as ...

Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an independent data monitoring committee.

Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why ...

A novel neoadjuvant therapy combining PD-1 blockade and chemoradiotherapy shows promising results in treating advanced rectal ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes how far the fanfare will spread. It’s more than just existing PD-1/L1 players ...

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PHILADELPHIA — A novel therapy targeting human ...

When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific ...

Eli Lilly has officially given up ex-China rights to Innovent Biologics’ Tyvyt, a PD-1 inhibitor that was once billed as a potential low-cost choice in a multibillion-dollar class. The drug was also ...